Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Aging Clin Exp Res ; 34(3): 505-514, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34398438

RESUMEN

BACKGROUND: The European Working Group on Sarcopenia in Older People (EWGSOP) recently updated the definition and diagnostic criteria to assess sarcopenia, which can result in important changes in sarcopenia prevalence in older adults. AIM: To compare the prevalence of sarcopenia through the diagnostic criteria and definition proposed by the first (EWGSOP1) and recent (EWGSOP2) European consensus in older adults. We also aimed to evaluate which sarcopenia consensus is better associated with unfavorable health outcomes. METHODS: The review followed PRISMA guidelines. Embase, Medline (PubMed), Scopus and Web of Science were searched from 2018 to February 2021. The systematic review protocol was registered at PROSPERO (CRD42020213303). The search, selection, and evaluation processes were done in a duplicate and independent manner. RESULTS: Of the 298 potentially eligible articles, 9 were included in this review. The prevalence of sarcopenia was 17.7% by EWGSOP1 and 11% by EWGSOP2. Evaluating all the studies, the sarcopenia prevalence ranged from 6.2 to 35.3% for the EWGSOP1, and from 3.2 to 26.3% for the EWGSOP2. Five studies have evaluated the association between the prevalence of sarcopenia (EWGSOP1 versus EWGSOP2) and unfavorable health outcomes, in which three studies showed that EWGSOP1 was better associated with increased risk of hospitalization and/or mortality. CONCLUSION: In comparison with EWGSOP1, the prevalence of sarcopenia in older adults decreased when diagnosed according to EWGSOP2. Based on limited evidence, EWGSOP2 seems to be worse for predicting unfavorable outcomes compared with EWGSOP1.


Asunto(s)
Sarcopenia , Anciano , Consenso , Fuerza de la Mano , Humanos , Prevalencia , Sarcopenia/complicaciones , Sarcopenia/diagnóstico , Sarcopenia/epidemiología
2.
Inflamm Res ; 65(2): 169-78, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26650032

RESUMEN

OBJECTIVE: The purpose of the study was to develop a novel diet based on standard AIN93G diet that would be able to induce experimental obesity and impair immune regulation with high concentrations of both carbohydrate and lipids. METHODS: To compare the effects of this high sugar and butter (HSB) diet with other modified diets, male C57BL/6 mice were fed either mouse chow, or AIN93G diet, or high sugar (HS) diet, or high-fat (HF) diet, or high sugar and butter (HSB) diet for 11 weeks ad libitum. HSB diet induced higher weight gain. Therefore, control AIN93G and HSB groups were chosen for additional analysis. Regulatory T cells were studied by flow cytometry, and cytokine levels were measured by ELISA. RESULTS: Although HF and HSB diets were able to induce a higher weight gain compatible with obesity in treated mice, HSB-fed mice presented the higher levels of serum glucose after fasting and the lowest frequency of regulatory T cells in adipose tissue. In addition, mice that were fed HSB diet presented higher levels of cholesterol and triglycerides, hyperleptinemia, increased resistin and leptin levels as well as reduced adiponectin serum levels. Importantly, we found increased frequency of CD4(+)CD44(+) effector T cells, reduction of CD4(+)CD25(+)Foxp3(+) and Th3 regulatory T cells as well as decreased levels of IL-10 and TGF-ß in adipose tissue of HSB-fed mice. CONCLUSION: Therefore, HSB represents a novel model of obesity-inducing diet that was efficient in triggering alterations compatible with metabolic syndrome as well as impairment in immune regulatory parameters.


Asunto(s)
Tejido Adiposo/inmunología , Dieta Alta en Grasa/efectos adversos , Carbohidratos de la Dieta/efectos adversos , Síndrome Metabólico/inmunología , Obesidad/inmunología , Linfocitos T Reguladores/inmunología , Adipoquinas/sangre , Animales , Glucemia/análisis , Colesterol/sangre , Grasas de la Dieta/efectos adversos , Interleucina-10/sangre , Interleucina-10/inmunología , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/etiología , Ratones Transgénicos , Obesidad/sangre , Obesidad/etiología , Factor de Crecimiento Transformador beta/sangre , Factor de Crecimiento Transformador beta/inmunología , Triglicéridos/sangre
3.
Br J Nutr ; 113(6): 935-43, 2015 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-25759975

RESUMEN

The aim of the present study was to investigate the effect of a protein-free diet in the induction of food allergy and oral tolerance in BALB/c mice. The experimental model used was mice that were fed, since weaning up to adulthood, a balanced diet in which all dietary proteins were replaced by amino acid diet (Aa). The absence of dietary proteins did not prevent the development of food allergy to ovalbumin (OVA) in these mice. However, Aa-fed mice produced lower levels of IgE, secretory IgA and cytokines. In addition, when compared with mice from control group, Aa-fed mice had a milder aversive reaction to the allergen measured by consumption of OVA-containing solution and weight loss during food allergy development. In addition, mice that did not have dietary proteins in their diets were less susceptible to induction of oral tolerance. One single oral administration was not enough to suppress specific serum Ig and IgG1 levels in the Aa-fed group, although it was efficient to induce suppression in the control group. The present results indicate that the stimulation by dietary proteins alters both inflammatory reactivity and regulatory immune reactivity in mice probably due to their effect in the maturation of the immune system.


Asunto(s)
Dieta con Restricción de Proteínas , Hipersensibilidad a los Alimentos/prevención & control , Tolerancia Inmunológica , Inmunidad Mucosa , Mucosa Intestinal/inmunología , Mucosa Bucal/inmunología , Aminoácidos/uso terapéutico , Animales , Caseínas/efectos adversos , Caseínas/uso terapéutico , Células Cultivadas , Citocinas/metabolismo , Dieta con Restricción de Proteínas/efectos adversos , Femenino , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad a los Alimentos/metabolismo , Hipersensibilidad a los Alimentos/patología , Inmunoglobulina A Secretora/análisis , Inmunoglobulina A Secretora/biosíntesis , Inmunoglobulina E/análisis , Inmunoglobulina E/biosíntesis , Inmunoglobulina G/análisis , Inmunoglobulina G/biosíntesis , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/patología , Linfocitos/inmunología , Linfocitos/metabolismo , Linfocitos/patología , Ratones Endogámicos BALB C , Mucosa Bucal/metabolismo , Destete , Pérdida de Peso
4.
Int J Food Sci Nutr ; 65(4): 489-94, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24456206

RESUMEN

The aim of the present study was to evaluate the potential of calcium supplementation from Lithothamnium muelleri algae on metabolic and inflammatory parameters in mice with increased adiposity. Male mice were fed and divided during 8 weeks in: control (C), a high refined carbohydrate-containing diet (HC), HC diet supplemented with 1% of Lithothamnion muelleri algae (HC + A) and HC diet supplemented with 0.9% calcium carbonate (HC + C). Animals fed HC diet had increased body weight gain and adiposity, serum glucose and cholesterol, glucose intolerance and decreased insulin sensitivity, compared to control diet. However, the HC + A and HC + C groups did not prevent these aspects and were not able to change the CD14 + cells population in adipose tissue of animals fed HC diet. Calcium supplementation with Lithothamnium muelleri algae and calcium carbonate had no protective effect against the development of adiposity, metabolic and inflammatory alterations induced by HC diet.


Asunto(s)
Adiposidad , Fármacos Antiobesidad/uso terapéutico , Calcio de la Dieta/uso terapéutico , Mezclas Complejas/uso terapéutico , Suplementos Dietéticos , Obesidad/prevención & control , Rhodophyta/química , Tejido Adiposo Blanco/irrigación sanguínea , Tejido Adiposo Blanco/inmunología , Tejido Adiposo Blanco/patología , Animales , Antiinflamatorios no Esteroideos/análisis , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/aislamiento & purificación , Antiinflamatorios no Esteroideos/uso terapéutico , Fármacos Antiobesidad/análisis , Fármacos Antiobesidad/química , Fármacos Antiobesidad/aislamiento & purificación , Vasos Sanguíneos/inmunología , Vasos Sanguíneos/patología , Carbonato de Calcio/administración & dosificación , Carbonato de Calcio/análisis , Carbonato de Calcio/aislamiento & purificación , Calcio de la Dieta/análisis , Calcio de la Dieta/aislamiento & purificación , Células Cultivadas , Mezclas Complejas/química , Carbohidratos de la Dieta/efectos adversos , Suplementos Dietéticos/análisis , Manipulación de Alimentos , Intolerancia a la Glucosa/etiología , Intolerancia a la Glucosa/prevención & control , Resistencia a la Insulina , Macrófagos/inmunología , Macrófagos/patología , Masculino , Ratones , Obesidad/etiología , Obesidad/inmunología , Obesidad/fisiopatología , Células del Estroma/inmunología , Células del Estroma/patología , Aumento de Peso
5.
J Nutr Biochem ; 57: 238-245, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29800810

RESUMEN

Dietary supplementation with conjugated linoleic acid (CLA) has been proposed for weight management and to prevent gut inflammation. However, some animal studies suggest that supplementation with CLA leads to the development of nonalcoholic fatty liver disease. The aims of this study were to test the efficiency of CLA in preventing dextran sulfate sodium (DSS)-induced colitis, to analyze the effects of CLA in the liver function, and to access putative liver alterations upon CLA supplementation during colitis. So, C57BL/6 mice were supplemented for 3 weeks with either control diet (AIN-G) or 1% CLA-supplemented diet. CLA content in the diet and in the liver of mice fed CLA containing diet were accessed by gas chromatography. On the first day of the third week of dietary treatment, mice received ad libitum a 1.5%-2.5% DSS solution for 7 days. Disease activity index score was evaluated; colon and liver samples were stained by hematoxylin and eosin for histopathology analysis and lamina propria cells were extracted to access the profile of innate cell infiltrate. Metabolic alterations before and after colitis induction were accessed by an open calorimetric circuit. Serum glucose, cholesterol, triglycerides and alanine aminotransaminase were measured; the content of fat in liver and feces was also accessed. CLA prevented weight loss, histopathologic and macroscopic signs of colitis, and inflammatory infiltration. Mice fed CLA-supplemented without colitis induction diet developed steatosis, which was prevented in mice with colitis probably due to the higher lipid consumption as energy during gut inflammation. This result suggests that CLA is safe for use during gut inflammation but not at steady-state conditions.


Asunto(s)
Colitis/dietoterapia , Ácidos Linoleicos Conjugados/farmacología , Enfermedad del Hígado Graso no Alcohólico/inducido químicamente , Alanina Transaminasa/sangre , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/farmacología , Colitis/inducido químicamente , Colitis/prevención & control , Colon/efectos de los fármacos , Colon/inmunología , Colon/patología , Sulfato de Dextran/toxicidad , Suplementos Dietéticos , Femenino , Inmunidad Innata/efectos de los fármacos , Inmunidad Innata/fisiología , Ácido Linoleico/metabolismo , Ácidos Linoleicos Conjugados/efectos adversos , Hígado/citología , Hígado/efectos de los fármacos , Hígado/metabolismo , Ratones Endogámicos C57BL
6.
J Immunol Methods ; 421: 36-43, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25707356

RESUMEN

The ability to avoid inflammatory responses to dietary components and microbiota antigens in the gut mucosa is achieved by a mechanism termed oral tolerance. This phenomenon is crucial to maintain the physiological immune activity in the gut and to prevent inflammatory disorders such as food allergy and inflammatory bowel diseases. Moreover, orally administered antigens induce regulatory cells that control systemic inflammatory responses as well. Given its specific, systemic and long-lasting effects, oral tolerance represents a promising approach for immunotherapies that aim to modulate inflammatory and autoimmune diseases. However, there are different protocols of feeding for induction of oral tolerance, and they have an impact in tolerance efficiency and length. Herein, we present and discuss different experimental feeding protocols and how they influence the outcome of oral administration of antigens.


Asunto(s)
Desensibilización Inmunológica/métodos , Tolerancia Inmunológica/inmunología , Inmunoglobulina E/sangre , Ovalbúmina/inmunología , Células TH1/inmunología , Administración Oral , Animales , Nutrición Enteral , Femenino , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad a los Alimentos/prevención & control , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/prevención & control , Mucosa Intestinal/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ovalbúmina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA